Treatment

Eunice S. Wang, MD

A Focus on Prognostic Indicators for Treatment in Patients with AML

Published on March 21, 2022 in Treatment

Eunice S. Wang, MD

What are the latest updates in the Phase 3 study of gilteritinib and AZA vs AZA alone for ND FLT-3 AML in patients ineligible for induction chemotherapy?

Published on February 28, 2022 in Treatment

Eunice S. Wang, MD

What is the current thinking on waiting for genetic information before starting treatment?

Published on February 23, 2022 in Treatment

E. Anders Kolb, MD

What are the treatment options for children with newly diagnosed treatment-related AML?

Published on January 24, 2022 in Treatment

E. Anders Kolb, MD

What are the most widely recognized treatment-related risk factors for secondary AML in children?

Published on January 10, 2022 in Treatment

E. Anders Kolb, MD

What puts children at risk for secondary AML?

Published on December 22, 2021 in Treatment

Brian A. Jonas, MD, PhD, FACP

When considering venetoclax plus azacitidine or decitabine, does a patient’s mutational status matter?

Published on December 15, 2021 in Treatment

Brian A. Jonas, MD, PhD, FACP

Venetoclax plus azacytidine, venetoclax plus decitabine or venetoclax plus low-dose cytarabine; how do you determine which combination therapy to use on your patients with AML?

Published on December 1, 2021 in Treatment

Brian A. Jonas, MD, PhD, FACP

Where does the combination of venetoclax with decitabine or azacitidine or LDAC fit in the treatment paradigm for AML?

Published on November 22, 2021 in Treatment

Amir T. Fathi, MD

What is the best approach to the therapy of patients with P53-mutated AML?

Published on November 10, 2021 in Treatment